Outsourcing-Pharma.com presents its latest round-up of the movers and shakers in the pharma service industry.
Ms Terry Robinson has been appointed Executive Director at Catalent’s Applied Drug Delivery Institute – an institute launched last year to blend industry and academic collaboration, research, education, and the sharing of information in order to accelerate drug delivery.
Ms. Robinson has been at Catalent since 2008 serving as Director of Global Accounts and has over 20 years of experience in the pharma industry.
Senior Vice President of Research and Development at Catalent, Dr. Kurt Nielsen said: “The appointment of an executive director is significant in strengthening the institute’s ability to foster better collaboration in drug development.”
Injectables manufacturer Hospira has appointed Royce R. Bedward (pictured) as corporate vice president, general counsel and secretary, effective immediately.
As one of the founding members of the Hospira legal team, Bedward will oversee the company’s legal department. Bedward has also served previously as Abbott’s senior counsel, litigation.
Hospira CEO F. Michael Ball said: “Royce is an accomplished lawyer and integrity-driven business leader with more than 10 years of experience in the healthcare field and a proven track record of success at Hospira”
Bedward will take over from Brian Smith who assumes the newly created role of chief legal officer, including responsibility for government affairs.
BioReliance, bought by Sigma-Aldrich in January 2012 and subsequently becoming the biologics and early development wing of SAFC, has named Archie Cullen (pictured) President.
Cullen has been Vice President of SAFC since 2009 and replaces Charles Harwood, who is retiring following the successful integration of BioReliance in the past year.
President of SAFC, Gilles Cottier said he was excited about Cullen’s appointment but found time to acknowledge Harwood: “Under his guidance BioReliance established a clear leadership position in providing critical services to the Biopharma industry.”
Albany Molecular Research (AMRI) has promoted Dr. Takeshi Yura to Vice President of Discovery and Development Services, Asia.
Yura has been at AMRI since 2011 leading the chemistry and biology teams in Singapore and prior to that role he was a director at Dishman Japan. He has also worked for Pfizer Japan and Bayer Yakuhin.
AMRI’s President, Chairman and CEO Dr. Thomas E. D'Ambra said: “With the ongoing evolution of outsourcing and a growing focus from customers on strategic relationships, we believe that Dr. Yura's leadership, his focus on excellence in scientific research and his dedication to quality and the integrity of our customers' intellectual property will provide integration under one leadership of what we are referring to as 'AMRI Asia.'”
Onyx Scientific has appointed a second business development professional, following the appointment of Dan Brisard (right) in November.
Adam Moorhouse (left) joins the contract research and manufacturing organisation as a Director of Business Development.
Vineet Luhariwala (centre), Business Unit head at Onyx Scientific, said: “Adam demonstrates a very high level of energy and enthusiasm that will no doubt make him a major asset to our business development team. His superb chemistry knowledge will equip him well to identify and pursue business opportunities with existing pharmaceutical and biotechnology clients and prospects on the West Coast.”
Cenduit, a provider of patient randomization and clinical supplies management services, has appointed Chris Dailey as Global Head of Technology.
The news comes in tandem with expansion plans to the company’s North Carolina headquarters and Swiss offices.
“The expansion and the acquisition of senior leadership like Chris give us the bandwidth to execute our plans to implement new technologies and augment the breadth of services that we provide to sponsors,” said CEO Jorgin Desai. “Our top priority is enabling investigator sites to achieve overall compliance through seamless management of patient enrollment and treatment throughout the clinical trial.”
Israeli medical device developer and commercialiser Exalenz Bioscience has announced Larry Cohen as the new CEO.
"I would like to congratulate Larry Cohen with his stepping into the role of Exalenz CEO,” said Exalenz Chairman Uri Geiger. “In light of the company's move into its sales and growth stage, and as a result of our deep commitment to extend the scope of the company's operations in the United States, we have decided to nominate an American CEO who has vast experience in the medical device arena.”
Nodality has announced the appointment of Dr. Guy Cavet as Chief Information Officer and Head of Computational Sciences.
Dr. Cavet comes to Nodality from Life Sciences at Kaggle where he served as Vice President and prior to that Crescendo Bioscience.
President and CEO of Nodality Laura Brege welcomed him aboard and added: “It is an exciting time for us as we expand the use of our technology platform among business partners and advance toward the commercialization of our first companion diagnostic products with oncology applications.”